| Literature DB >> 28826408 |
Pedro Freire Jorge1, Nienke Wieringa1, Eva de Felice1, Iwan C C van der Horst1, Annemieke Oude Lansink1, Maarten W Nijsten2.
Abstract
BACKGROUND: The development of renal and liver dysfunction may be accompanied by initially subtle derangements in the gluconeogenetic function. Discrepantly low glucose levels combined with high lactate levels might indicate an impaired Cori cycle. Our objective was to examine the relation between early lactate and glucose levels with subsequent renal and liver dysfunction and hospital mortality in critically ill patients.Entities:
Keywords: Acute kidney injury; Cori cycle; Critical illness; Glucose; Lactate; Liver dysfunction; Metabolism; Mortality; Organ failure
Mesh:
Substances:
Year: 2017 PMID: 28826408 PMCID: PMC5563890 DOI: 10.1186/s13054-017-1785-z
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Laboratory and clinical outcomes
| Variable | All patients | Hospital survivors | Hospital nonsurvivors |
|
|---|---|---|---|---|
| Number of combined lactate/glucose measurements per patient in first 24 h | 10 (7–12) | 10 (7–12) | 11 (8–14) | <0.001 |
| Mean lactate (mmol/l) | 1.5 (1.1–2.9) | 1.5 (1.1–2.0) | 1.9 (1.3–3.2) | <0.001 |
| Mean glucose (mmol/l) | 7.9 (7.1–8.7) | 7.8 (7.1–8.7) | 8.2 (7.3–9.3) | <0.001 |
| Hypoglycemia incidence (per patient) | ||||
| Any glucose <2.2 mmol/L | 0.4% (34) | 0.3% (21) | 1.3% (13) | <0.001 |
| Any glucose <3.3 mmol/L | 1.8% (162) | 1.4% (109) | 5.3% (53) | <0.001 |
| Any glucose <4.0 mmol/L | 4.3% (390) | 3.5% (285) | 10.4% (105) | <0.001 |
| Baseline creatinine (μmol/L) | 81 (67–102) | 80 (66–99) | 95 (70–141) | <0.001 |
| Maximal creatinine (μmol/L) | 81 (65–109) | 79 (64–103) | 123 (80–219) | <0.001 |
| AKI | 20.4% (7224) | 16.9% (6707) | 51.3% (517) | <0.001 |
| Stage 1 | 9.9% (894) | 9.2% (740) | 15.3% (154) | <0.001 |
| Stage 2 | 3.5% (319) | 2.8% (223) | 9.5% (96) | <0.001 |
| Stage 3 | 7.3% (664) | 4.9% (397) | 26.5% (267) | <0.001 |
| Baseline bilirubin (μmol/L) | 8 (6–14) | 8 (5–13) | 9 (6–18) | <0.001 |
| Maximal bilirubin (μmol/L) | 10 (7–15) | 10 (7–15) | 12 (8–24) | <0.001 |
| Baseline ALT (IU/L) | 25 (17–42) | 25 (17–40) | 31 (66–18) | <0.001 |
| Maximal ALT (IU/L) | 34 (20–70) | 32 (19–64) | 57 (27–177) | <0.001 |
| Baseline AST (IU/L) | 28 (22–45) | 27 (21–42) | 41 (25–92.5) | <0.001 |
| Maximal AST (IU/L) | 51 (30–101) | 48 (30–89) | 97.5 (44–323.5) | <0.001 |
| Baseline GGT (IU/L) | 37 (23–71) | 36 (23–67) | 49 (27–107) | <0.001 |
| Maximal GGT (IU/L) | 43 (21–106) | 39 (20–98) | 75 (36.5–152) | <0.001 |
| Baseline AP (IU/L) | 72 (57–93) | 71 (57–91) | 80 (58–119) | <0.001 |
| Maximal AP (IU/L) | 72 (54–108) | 71 (53–104) | 89 (63–141) | <0.001 |
| Baseline PT (IU/L) | 12.1 (11.3–14.1) | 12.1 (11.2–14) | 12.9 (11.5–15.6) | <0.001 |
| Maximal PT (IU/L) | 12.7 (11.9–14.2) | 12.6 (11.8–14.0) | 14.0 (12.1–18.6) | <0.001 |
| ICU length of stay (days) | 1.0 (0.9–3.5) | 1.0 (0.9–2.8) | 3.9 (1.6–9.4) | <0.001 |
| Hospital length of stay (days) | 11.1 (7.1–19.1) | 11.2 (7.2–19.2) | 7.3 (2.9–17.5) | <0.001 |
Values are presented as % (n) or medians (interquartile range) as appropriate
AKI acute kidney injury, ALT alanine aminotransferase, AP alkaline phosphatase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, ICU intensive care unit, PT prothrombin time
Patient characteristics
| Variable | All patients | Hospital survivors | Hospital nonsurvivors |
|
|---|---|---|---|---|
| Age, years | 64 (53–72) | 64 (53–72) | 66 (56–75) | <0.001 |
| Male | 63% (5719) | 63.4% (5118) | 59.7% (601) | 0.02 |
| Admission through ED | 27% (2415) | 24.0% (1935) | 47.7% (480) | <0.001 |
| Type of admission | ||||
| Medical | 7.0% (632) | 6.7% (540) | 9.1% (70) | 0.006 |
| Vascular, abdominal, miscellaneous surgery | 20.9% (1900) | 22% (1775) | 12.4% (125) | <0.001 |
| Neurosurgery | 9.8% (893) | 10.7% (866) | 2.7% (27) | <0.001 |
| Transplantation | 1.2% (112) | 1.3% (104) | 0.8% (8) | NS |
| Cardiothoracic surgery | 41.0% (3716) | 43.9% (3542) | 17.3% (174) | <0.001 |
| Trauma | 3.1% (280) | 3.2% (258) | 2.2% (22) | NS |
| Miscellaneous | 17.0% (1541) | 12.2% (982) | 55.5% (559) | <0.001 |
| APACHE IV score | 48 (35–64) | 45 (33–59) | 87 (67–113) | <0.001 |
| Body mass index, kg/m2 | 25.9 (23.5–28.7) | 26.0 (23.7–28.8) | 25.5 (23.1–28.2) | 0.001 |
| Diabetes | 17% (1534) | 16.6% (1337) | 19.6% (197) | 0.02 |
| Mean 24 h insulin (IU/h) | 0.63 (0.08–1.35) | 0.62 (0.06–1.31) | 0.77 (0.16–1.74) | <0.001 |
| Steroids within 18 h of ICU admission | 13% (1209) | 12.0% (966) | 24.1% (243) | <0.001 |
Values are presented as % (n) or medians (interquartile range) as appropriate
APACHE Acute Physiology and Chronic Health Evaluation, ED emergency department, ICU intensive care unit, NS not significant
Fig. 1Univariate relationship between lactate and glucose and mortality. Lactate quintiles and hospital mortality (left panel) and glucose quintiles and hospital mortality (right panel). Note the U-shaped relationship for glucose. Both relationships deviate from the uniform distribution (p < 0.001)
Regression analyses
*The statistical inference in the logistic regression is presented as an odds ratio (OR) (95% confidence interval (CI)) and in the linear regression as a β-coefficient (β) (95% CI)
Multivariate analyses for renal dysfunction (acute kidney injury (AKI); top third of table), liver dysfunction (maximal bilirubin; middle third of table), and mortality (bottom third of table) were performed with and without Acute Physiology and Chronic Health Evaluation (APACHE) IV (AP-IV) as an independent factor
Regression analyses are shown between lactate quintiles (L), glucose quintiles (G), (glucose quintile – mean)2 (G–m)2, and the interaction term (lactate quintile × glucose quintile (L × G)), and outcome
In order to accommodate for the known U-shaped relationship of glucose with outcome, the squared factor (glucose quintile – mean glucose quintile)2 is used. The term (lactate quintile × glucose quintile) was used to verify an interaction between lactate and glucose
Note the for both for AKI and mortality, the addition of the squared factor and of the interaction term improved the contribution of glucose in the multivariate model
NS not significant
Fig. 2Multivariate relationship of lactate and glucose with renal and liver dysfunction. Combined early lactate and glucose and incidence of subsequent acute kidney injury (AKI; upper panel) and liver dysfunction as reflected by maximal bilirubin (lower panel). Note that the outcome is worst in the upper left corners, reflecting patients with the highest lactate and lowest glucose (p < 0.001)
Fig. 3Lactate and glucose and mortality. Combined early lactate and glucose quintiles and hospital mortality. Note the sharply different mortality rates for the various combinations of lactate and glucose. The highest mortality rate is seen in patients in the upper left corner, i.e., with a mean lactate >2.3 mmol/L and a mean glucose ≤7.0 mmol/L (p < 0.001)
Fig. 4Mean lactate levels according to glucose quintile in survivors and nonsurvivors. Error bars represent the standard error of the mean. Note that in the lowest glucose quintile lactate levels are most discrepant between survivors and nonsurvivors. *p < 0.001 between survivors and nonsurvivors